Last updated: October 2026
The leading AI tools for prostate biopsy pathology in 2026 include Paige Prostate (now part of Tempus), Ibex Prostate Detect and ArteraAI Prostate, which all hold FDA authorization or clearance, along with DeepDx Prostate, AIRAProstate, Aiforia’s Prostate Cancer Suite and Qritive’s QAi Prostate Grade. They help pathologists find small cancers on prostate biopsies, grade them consistently and, increasingly, predict how a patient’s disease will behave, giving urologists a more reliable report to act on.
Prostate is where pathology AI is most mature. Biopsies are high-volume and standardized, every core matters to the patient, and Gleason grading varies between pathologists, which is exactly where AI helps most. Below, we compare the leading tools, explain what each one does and look at the step that determines how well any of them works: the tissue itself. The list is alphabetical by company, not a ranking.
In this guide
- What prostate AI does
- Comparison at a glance
- The top AI tools for prostate pathology
- Why tissue handling matters for prostate AI
- How to choose a prostate AI tool
- Frequently asked questions
What Prostate AI Does
Prostate pathology AI generally does one of three jobs:
- Detection: flags areas on a core biopsy that are suspicious for cancer, acting as a second set of eyes so small or subtle cancers aren’t missed.
- Grading and quantification: assigns Gleason patterns and grade groups, measures tumor length and percentage, and flags features like perineural invasion or cribriform patterns, which reduces variability and saves time on reporting.
- Prognosis and prediction: combines the slide image with clinical data to estimate how the cancer will behave and which treatments a patient is likely to benefit from.
Some tools do more than one job. Knowing which job you need is the first step in choosing.
Comparison at a Glance
| Tool | Company | Main job | Regulatory status | Works in Lumea’s viewer |
|---|---|---|---|---|
| AIRAProstate | AIRA Matrix | Grading and quantification | — | Yes |
| Prostate Cancer Suite | Aiforia | Detection and feature detection | CE marked (Europe) | No |
| ArteraAI Prostate | Artera | Prognosis and therapy benefit | FDA De Novo (2025); CE marked | Yes |
| DeepDx Prostate | Deep Bio | Detection, grading and quantification | Approved in South Korea and Switzerland; research use only in the U.S. | Yes |
| Ibex Prostate Detect | Ibex Medical Analytics | Detection | FDA 510(k) (2025); Galen Prostate CE-IVD (Europe) | No |
| Paige Prostate | Tempus (Paige) | Detection | FDA De Novo (2021); CE-IVD | Yes |
| QAi Prostate Grade | Qritive | Detection and grading | — | No |
A dash means we couldn’t confirm a regulatory clearance as of October 2026. Check current status and intended use with each vendor.
The Top AI Tools for Prostate Pathology
1. AIRA Matrix: AIRAProstate
Based in Mumbai, India, AIRA Matrix develops AI for cancer diagnosis with a strong focus on prostate. AIRAProstate analyzes prostate biopsies and radical prostatectomies to deliver Gleason scores, ISUP grade groups, tumor percentage and perineural invasion assessment across multi-slide, multi-core cases.
2. Aiforia: Prostate Cancer Suite
Finland-based Aiforia offers a suite of prostate models: one for cancer detection on biopsies and others that detect perineural invasion, Gleason grade 4 cribriform patterns and high-grade prostatic intraepithelial neoplasia (HG-PIN), features that are time-consuming and subjective to assess by eye.
3. Artera: ArteraAI Prostate
Artera’s multimodal AI combines a patient’s biopsy image with a few clinical variables (tumor stage, PSA and age) to estimate long-term outcomes and predict benefit from specific treatments. In August 2025, the FDA granted De Novo authorization to ArteraAI Prostate, the first AI software authorized to predict long-term outcomes for patients with non-metastatic prostate cancer.
4. Deep Bio: DeepDx Prostate
Based in South Korea, Deep Bio’s DeepDx Prostate detects cancer on H&E-stained core biopsies, grades it on the Gleason system, and measures the proportion of each Gleason pattern along with total tumor and tissue length, analyzing a whole slide in under 30 seconds. It is approved for clinical use in South Korea and Switzerland and available for research use in the U.S.
5. Ibex Medical Analytics: Ibex Prostate Detect
Ibex Prostate Detect received FDA 510(k) clearance in February 2025. It works as a safety net, highlighting areas of potential cancer on prostate biopsy images so pathologists can catch small or rare cancers they might otherwise miss. Outside the U.S., Ibex’s Galen Prostate is CE-IVD marked.
6. Paige (Tempus): Paige Prostate
Paige Prostate was the first AI product in pathology authorized by the FDA, through the De Novo pathway in 2021. It identifies areas on a prostate biopsy most likely to contain cancer so the pathologist can review them. In the study behind the authorization, pathologists using it improved their cancer detection by 7.3% on average. Paige, built on Memorial Sloan Kettering’s digital slide archive, was acquired by Tempus in 2025.
7. Qritive: QAi Prostate Grade
Singapore-based Qritive’s QAi Prostate analyzes whole slide images of prostate core needle biopsies, separates benign from malignant areas and summarizes tumor size and percentage for each slide, with grading built into QAi Prostate Grade.
Looking beyond prostate? See our list of the top 10 AI companies for digital pathology.
Why Tissue Handling Matters for Prostate AI
AI can only analyze what makes it onto the slide. If biopsy cores fragment, twist or lose their orientation on the way from the procedure room to the lab, there’s less tissue for both the pathologist and the algorithm to read, and the location of each core can be lost.
That’s why Lumea’s approach starts before the scanner. The BxBoard replaces formalin jars with site-specific lanes on a formalin-soaked sponge that keep up to six cores flat and oriented. In the lab, the cores move to the BxChip, a tissue array that holds them in a single plane through processing, embedding and sectioning. Published research on this workflow found an 18.79% higher prostate cancer detection rate.
“We’re all doctors. We all got into this field for a reason: the patient is central to everything we do,” says Dr. Adam Cole, a genitourinary pathologist who uses Lumea’s workflow with AI on his prostate cases. His practice reports cancer detection rates of about 60%, compared with a national average of 45% to 50%, and a 50% reduction in diagnostic time per case, helped by AI features like automated tumor size and involvement percentage that fill in the pathology report as he annotates.
Several of the tools above, including Paige Prostate, ArteraAI Prostate, DeepDx Prostate and AIRAProstate, run inside Lumea’s Viewer+. See them all in the Partner Marketplace.
How to Choose a Prostate AI Tool
- Match the tool to the job. Detection, grading and prognosis are different problems. A detection tool won’t give your urologists a risk estimate, and a prognostic test won’t catch a missed focus of cancer.
- Check the intended use. FDA clearance or authorization covers a specific use on specific specimens. Using a tool outside that scope means your lab validates it as a laboratory-developed test.
- Test it on your own cases. Ask for validation data on biopsies like yours, from scanners like yours, and run your own cases before you commit.
- Keep it in the viewer. AI results that appear alongside the slide where you sign out get used. Results in a separate application often don’t.
For a full implementation plan, see How to Implement Digital Pathology.
Frequently Asked Questions
Is there FDA-approved AI for prostate cancer pathology?
Yes. Paige Prostate received FDA De Novo authorization in 2021, Ibex Prostate Detect received 510(k) clearance in 2025 and ArteraAI Prostate received De Novo authorization in 2025. The first two help detect cancer on biopsies; ArteraAI Prostate predicts long-term outcomes.
What AI tools help urologists interpret prostate biopsy results?
Pathologists use detection and grading tools to make the diagnosis more accurate and consistent, which gives urologists a more reliable Gleason grade and tumor measurements. Prognostic tools like ArteraAI Prostate go a step further, giving urologists and oncologists a risk estimate and an indication of which patients are likely to benefit from specific therapies.
Can AI grade prostate cancer?
Several tools, including DeepDx Prostate, AIRAProstate and QAi Prostate Grade, assign Gleason patterns and grade groups and measure tumor extent. The pathologist reviews the results and makes the final diagnosis.
Will AI replace pathologists in prostate cancer diagnosis?
No. Prostate AI flags areas to review, quantifies features and predicts outcomes, but the pathologist makes the diagnosis. With biopsy volumes rising and pathologists in short supply, AI is best understood as a way to extend their capacity and consistency.
See Prostate AI in Your Workflow
Want to see how AI and better tissue handling work together on your own prostate cases? Request a demo.
